Annals of Oncology 12:47-51, 2001
© 2001 European Society for Medical Oncology
research-article |
Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer
1Department of Surgery, Otto von Guencke University Medical School
2Department of Oncology, Städusches Klmikum, Magdeburg, Germany
Dr K Ridwelski Chirurgische Klinik Medizinische Fakultat Otto von Guencke Universität 39120 Magdeburg Germany Karsten.Ridwelski{at}Medizin.Um-Magdeburg.de
BACKGROUND: Poor treatment results obtained with palliative chemotherapy for advanced gastric cancer indicate the need for new effective and well-tolerated regimens
PATIENTS AND METHODS: Forty-three patients with locally advanced or metastatic gastric cancer were enrolled in a phase II study to evaluate the efficacy and safety of combination chemotherapy with doxetacel 75 mg/m2 and cisplatin 75 mg/m2 given every three weeks
RESULTS: Thirty-nine patients were evaluable for response Four achieved a complete response and twelve a partial response, for an overall response rate of 37.2% (16 of 43 patients; 95% confidence interval (CI) 22 98–53 72) Median time to progression was 6 1 months and median overall survival 10 4 months Forty-two percent of all patients were still alive at one year and twelve percent at two years The major toxicity was leukopenia which reached grade 3–4 in 18.6% (n = 8) of the patients However, no febrile neutropenia occurred Nonhaematological toxicities were usually mild to moderate Grade 3 toxicities included diarrhea (9% of the patients), nausea and vomiting (7%), and alopecia (7%). Severe ototoxicity with or without peripheral neuropathy developed after completion of chemotherapy in two patients.
CONCLUSIONS: These results suggest that the combination of docetaxel and cisplatin has moderate toxicity and is an effective regimen for the treatment of advanced gastric cancer, both with regard to response rate and survival.
advanced gastric cancer, cisplatin, combination chemotherapy, docetaxel, metastatic gastric cancer
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  Q. Sun, C. Liu, H. Zhong, B. Zhong, H. Xu, W. Shen, and D. Wang Multi-center Phase II Trial of Weekly Paclitaxel Plus Cisplatin Combination Chemotherapy in Patients with Advanced Gastric and Gastro-esophageal Cancer Jpn. J. Clin. Oncol., April 1, 2009; 39(4): 237 - 243. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Lorenzen, M. Hentrich, C. Haberl, V. Heinemann, T. Schuster, T. Seroneit, N. Roethling, C. Peschel, and F. Lordick Split-dose docetaxel, cisplatin and leucovorin/fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trial Ann. Onc., October 1, 2007; 18(10): 1673 - 1679. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. D. Roth, N. Fazio, R. Stupp, S. Falk, J. Bernhard, P. Saletti, D. Koberle, M. M. Borner, K. Rufibach, R. Maibach, et al. Docetaxel, Cisplatin, and Fluorouracil; Docetaxel and Cisplatin; and Epirubicin, Cisplatin, and Fluorouracil As Systemic Treatment for Advanced Gastric Carcinoma: A Randomized Phase II Trial of the Swiss Group for Clinical Cancer Research J. Clin. Oncol., August 1, 2007; 25(22): 3217 - 3223. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Van Cutsem, V. M. Moiseyenko, S. Tjulandin, A. Majlis, M. Constenla, C. Boni, A. Rodrigues, M. Fodor, Y. Chao, E. Voznyi, et al. Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study Group J. Clin. Oncol., November 1, 2006; 24(31): 4991 - 4997. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ezziddin, T. Logvinski, C. Yong-Hing, H. Ahmadzadehfar, H.-P. Fischer, H. Palmedo, J. Bucerius, M. J. Reinhardt, and H.-J. Biersack Factors Predicting Tracer Uptake in Somatostatin Receptor and MIBG Scintigraphy of Metastatic Gastroenteropancreatic Neuroendocrine Tumors J. Nucl. Med., February 1, 2006; 47(2): 223 - 233. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kim, J.-H. Park, S.-J. Bang, D.-H. Kim, H. R. Cho, G. Y. Kim, and Y. J. Min A Phase II Study of Docetaxel and Cisplatin in Patients with Gastric Cancer Recurring After or Progressing During 5-FU/Platinum Treatment Jpn. J. Clin. Oncol., December 1, 2005; 35(12): 727 - 732. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K.-W. Lee, S.-A. Im, T. Yun, E. K. Song, I. i. Na, H. Shin, I. S. Choi, D.-Y. Oh, J. H. Kim, D.-W. Kim, et al. Phase II Trial of Low-dose Paclitaxel and Cisplatin in Patients with Advanced Gastric Cancer Jpn. J. Clin. Oncol., December 1, 2005; 35(12): 720 - 726. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Ajani Evolving Chemotherapy for Advanced Gastric Cancer Oncologist, October 1, 2005; 10(suppl_3): 49 - 58. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Di Lauro, F. Belli, M. G. Arena, S. Carpano, G. Paoletti, D. Giannarelli, and M. Lopez Epirubicin, cisplatin and docetaxel combination therapy for metastatic gastric cancer Ann. Onc., September 1, 2005; 16(9): 1498 - 1502. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Ajani, M. B. Fodor, S. A. Tjulandin, V. M. Moiseyenko, Y. Chao, S. C. Filho, A. Majlis, S. Assadourian, and E. Van Cutsem Phase II Multi-Institutional Randomized Trial of Docetaxel Plus Cisplatin With or Without Fluorouracil in Patients With Untreated, Advanced Gastric, or Gastroesophageal Adenocarcinoma J. Clin. Oncol., August 20, 2005; 23(24): 5660 - 5667. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. G. Fakih, P. J. Creaven, N. Ramnath, D. Trump, M. Javle, S. Strychor, T. V.W. Repinski, B. A. Zamboni, J. K. Schwarz, R. A. French, et al. Phase I and Pharmacokinetic Study of Weekly Docetaxel, Cisplatin, and Daily Capecitabine in Patients with Advanced Solid Tumors Clin. Cancer Res., August 15, 2005; 11(16): 5942 - 5949. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D.-Y. Oh, T.-Y. Kim, J. H. Kwon, J.-J. Lee, Y. Joh, D.-W. Kim, T.-Y. Kim, D. S. Heo, Y.-J. Bang, and N. K. Kim Docetaxel + 5-Fluorouracil + Cisplatin 3-day Combination Chemotherapy as a First-line Treatment in Patients with Unresectable Gastric Cancer Jpn. J. Clin. Oncol., July 1, 2005; 35(7): 380 - 385. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. C. Thuss-Patience, A. Kretzschmar, M. Repp, D. Kingreen, D. Hennesser, S. Micheel, D. Pink, C. Scholz, B. Dorken, and P. Reichardt Docetaxel and Continuous-Infusion Fluorouracil Versus Epirubicin, Cisplatin, and Fluorouracil for Advanced Gastric Adenocarcinoma: A Randomized Phase II Study J. Clin. Oncol., January 20, 2005; 23(3): 494 - 501. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. S. Wohrer, M. Raderer, and M. Hejna Palliative chemotherapy for advanced gastric cancer Ann. Onc., November 1, 2004; 15(11): 1585 - 1595. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Van Cutsem The Treatment of Advanced Gastric Cancer: New Findings on the Activity of the Taxanes Oncologist, June 2, 2004; 9(suppl_2): 9 - 15. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Diaz-Rubio New Chemotherapeutic Advances in Pancreatic, Colorectal, and Gastric Cancers Oncologist, June 1, 2004; 9(3): 282 - 294. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. D. Roth, R. Maibach, N. Fazio, C. Sessa, R. Stupp, R. Morant, R. Herrmann, M. M. Borner, A. Goldhirsch, and F. de Braud 5-Fluorouracil as protracted continuous intravenous infusion can be added to full-dose docetaxel (Taxotere(R))-cisplatin in advanced gastric carcinoma: a phase I-II trial Ann. Onc., May 1, 2004; 15(5): 759 - 764. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Assersohn, G. Brown, D. Cunningham, C. Ward, J. Oates, J. S. Waters, M. E. Hill, and A. R. Norman Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma Ann. Onc., January 1, 2004; 15(1): 64 - 69. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. D. Roth Chemotherapy in gastric cancer: a never ending saga Ann. Onc., February 1, 2003; 14(2): 175 - 177. [Full Text] [PDF]
|
|
|
|
|
|
Y.-J. Bang, W. K. Kang, Y.-K. Kang, H. C. Kim, C. Jacques, E. Zuber, B. Daglish, Y. Boudraa, W. S. Kim, D. S. Heo, et al. Docetaxel 75 mg/m2 is Active and Well Tolerated in Patients with Metastatic or Recurrent Gastric Cancer: a Phase II Trial Jpn. J. Clin. Oncol., July 1, 2002; 32(7): 248 - 254. [Abstract] [Full Text] [PDF]
|
|